E-Book, Englisch, Band 127, 300 Seiten, eBook
Senn / Gelber / Goldhirsch Adjuvant Therapy of Breast Cancer IV
Erscheinungsjahr 2012
ISBN: 978-3-642-84745-5
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
E-Book, Englisch, Band 127, 300 Seiten, eBook
Reihe: Recent Results in Cancer Research
ISBN: 978-3-642-84745-5
Verlag: Springer
Format: PDF
Kopierschutz: 1 - PDF Watermark
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
I. Biological Mechanisms and Models.- Kinetic Concepts in the Treatment of Breast Cancer.- Tumor Stem Cells and the Curability of Early Human Breast Cancer.- A New Paradigm for Breast Cancer.- A Laboratory Model To Explain the Survival Advantage Observed in Patients Taking Adjuvant Tamoxifen Therapy.- Growth Factors and Angiogenesis in Breast Cancer.- Mechanisms of Treatment Failure.- Expression of the MDR1 Gene (P-Glycoprotein) in Breast Cancer.- II. Prognosis and Prediction of Response.- Prognosis of Breast Cancer Patients: How To Use What?.- DNA Flow Cytometry Measurements and Their Clinical Relevance in Node-Negative Breast Cancer Patients.- Review of Proliferative Variables and Their Predictive Value.- Critical Review of Growth Factors as Clinical Tools in Primary and Metastatic Breast Cancer.- Prognosis and Prediction for Early Breast Cancer.- III. Primary Therapy for Early Breast Cancer.- Trials of Breast Conservation: A Critical Review of All Options.- Selection and Technique for Lumpectomy.- Salvage Treatment After Local Breast Cancer Relapse.- Primary Chemotherapy for Resectable Breast Cancer.- IV. Radiation Therapy as Part of Primary Treatment.- Radiation Therapies for Breast Cancer: Current Knowledge of Advantages and Disadvantages.- How To Combine Adjuvant Chemotherapy and Radiation Therapy.- Factors Which Predict Breast Relapse.- Summary Report: Radiation Therapy as Part of Primary Treatment.- V. Adjuvant Systemic Therapy: Overview and Improvement of Therapy.- Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy: 133 Randomised Trials Involving 31000 Recurrences and 24 000 Deaths Among 75 000 Women (Summary).- What Did We Learn from the Results of the International Overview about the Effects of Endocrine Therapy?.- The WorldOverview at 10 Years: What Did We Learn about the Results of Chemotherapy?.- From the Overview to the Patient: How To Interpret Meta-analysis Data.- High-Dose Adjuvant Chemotherapy for High-Risk Breast Cancer.- Maintenance Tamoxifen After Induction Postoperative Chemotherapy in Node-Positive Breast Cancer Patients: The Eastern Cooperative Oncology Group Trials.- Adjuvant Systemic Therapy: Overview.- VI. Quality-of-Life Considerations in the Adjuvant Setting.- Assessment of Quality of Life and Benefits from Adjuvant Therapies in Breast Cancer.- Coping and Survival in Early Breast Cancer: An Update.- How To Compare Quality of Life of Breast Cancer Patients in Clinical Trials.- Psychosocial Issues in Breast Cancer Clinical Trials.- Quality-of-Life Considerations in the Adjuvant Setting: Critical Review.- VII. Long-Term Toxicity and Economic Aspects.- Long-Term Sequelae from Adjuvant Chemotherapy.- Long-Term Toxicity of Tamoxifen.- New Endocrine Agents for the Treatment of Breast Cancer.- Financial Costs, Benefits, and Patient Risk Preferences in Node-Negative Breast Cancer: Insights from a Decision Analysis Model.- Long-Term Toxicity and Economic Aspects: Critical Review.- VIII. Conclusion.- Adjuvant Therapy of Primary Breast Cancer: Closing Summary.